Abbott Laboratories (ABT) Net Income towards Common Stockholders (2009 - 2026)

Abbott Laboratories has disclosed Net Income towards Common Stockholders across 18 years of filings, most recently posting $1.1 billion for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at $1.1 billion, down 18.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.3 billion (down 53.52% YoY), and the FY2025 annual result was $6.5 billion, down 51.32% from the prior year.
• Net Income towards Common Stockholders came in at $1.1 billion for Q1 2026 at Abbott Laboratories, down from $1.8 billion in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $9.2 billion in Q4 2024 to a low of $1.0 billion in Q4 2022.
• The 5-year median for Net Income towards Common Stockholders is $1.4 billion (2023), against an average of $2.0 billion.
• Across the five-year window, Net Income towards Common Stockholders jumped 478.98% in 2024 and sank 80.76% in 2025, its largest moves.
• Abbott Laboratories' Net Income towards Common Stockholders stood at $1.0 billion in 2022, then jumped by 54.31% to $1.6 billion in 2023, then surged by 478.98% to $9.2 billion in 2024, then tumbled by 80.76% to $1.8 billion in 2025, then slumped by 39.36% to $1.1 billion in 2026.
• The last three Net Income towards Common Stockholders figures came in at $1.1 billion (Q1 2026), $1.8 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.